Novartis has announced its biologic Cosentyx (secukinumab) was superior to AbbVie’s blockbuster Humira...
- Novartis’ Cosentyx outperforms Humira in PsA-specific endpoints
- FDA approves Janssen’s Stelara for adults with UC
- EC expands label of Janssen’s Stelara to include ulcerative colitis
- Psoriasis Action Month: using genetics to improve drug development
- Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials
Novartis’ Cosentyx outperforms Humira in PsA-specific endpoints
Novartis has announced its biologic Cosentyx (secukinumab) was superior to AbbVie’s blockbuster Humira (adalimumab) in psoriatic arthritis (PsA) endpoints of the EXCEED head-to-head trial.
Metabolic disorders on Twitter: Diabetes leads mentions in August 2019
Pharmaceutical Technology lists the top tweeted terms on metabolic disorders in August 2019, based in data from GlobalData’s Influencer Platform.
EC expands label of Janssen’s Stelara to include ulcerative colitis
Johnson & Johnson subsidiary Janssen has announced the European Commission (EC) has approved Stelara (ustekinumab) for patients with moderately to severely active ulcerative colitis (UC).
Psoriasis Action Month: using genetics to improve drug development
The role of a patient’s genes in causing inflammatory skin condition psoriasis has been largely accepted in the medical community over the past few decades. This has led to significant research into precisely which genes are associated with the condition and how this understanding can better inform drug development, as well as ensure there are effective treatments for more patients.
US court rules in favour of Amgen in Enbrel patent case
The US District Court for the District of New Jersey has upheld two of Amgen’s patents that claim its rheumatoid arthritis drug Enbrel (etanercept) and methods for making the medicine.
Terns to commercialise GENFIT’s elafibranor to treat NASH and PBC
Terns Pharmaceuticals has signed an agreement to acquire the exclusive rights to develop, register and market GENFIT’s elafibranor.
Janssen’s Tremfya shows promise in two Phase III psoriatic arthritis trials
Johnson & Johnson subsidiary Janssen has announced that Tremfya (guselkumab) reached its primary endpoint in the Phase III DISCOVER one and two studies, where it is being investigated for adults with moderate to severe psoriatic arthritis.
Diabetes Week: investigating the immune basis of type 1 diabetes
Diabetes UK use its annual Diabetes Week to raise awareness, as well as funds for, among other things, crucial research into new treatments for diabetes. One largely neglected therapeutic approach the charity has invested in is repurposing immunotherapies from other autoimmune diseases for type 1 diabetes, linked with the immune system’s role in destroying pancreatic cells.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.